Epstein-Barr Virus (EBV) and Infectious Mononucleosis

Ever had a sore throat that just would not go away? Maybe it also came with bone-deep fatigue that made every activity feel like a marathon? You may have dismissed it as a bad cold but it could have been something more serious. One of the most prevalent viruses in the world is EBV, especially considering that more than 90% of adults have been infected at some time. In most cases, it produces no noticeable disease, yet in adolescents and young adults it frequently manifests itself as infectious mononucleosis.

EBV has significant clinical implications. It has been epidemiologically associated with the incidence of some tumors in specific populations and has been reported to increase the risk of developing multiple sclerosis. The relationships are complicated (EBV alone is neither a necessary nor sufficient cause of these diseases) but relevant to actions on public health and vaccine research priorities.

In this article, we will explain what EBV is, how it transmits, the symptoms to watch for, and when one should visit a doctor. As a patient in need of straightforward information or a clinician in need of a middle-ground refresher, here are answers to your EFV-related questions and everything about managing EBV infection.

Epstein-Barr virus is a type of a virus. It is a member of a family of herpesviruses and has the double-stranded DNA. It is a Gamma-herpesvirus lymphotropic that has a tendency of infecting B cells and epithelial cells and was initially found in 1964 in a cell line obtained out of Burkitt lymphoma cells.

BV is one of the most prevalent human viruses throughout the world. There is an increasing incidence of seroprevalence with age. Infection starts as early as mid-adolescence in resource-limited countries; later in high-income countries. The majority of childhood infections are asymptomatic or mild. Infections in adolescence or young adults are much more likely to cause symptomatic infection known as infectious mononucleosis ("mono"). Following the initial infection the virus stays in a long term latency, usually incorporated in B cells.

Epstein-Barr virus is a type of a virus. It is a member of a family of herpesviruses and has the double-stranded DNA. It is a Gamma-herpesvirus lymphotropic that has a tendency of infecting B cells and epithelial cells and was initially found in 1964 in a cell line obtained out of Burkitt lymphoma cells.

BV is one of the most prevalent human viruses throughout the world. There is an increasing incidence of seroprevalence with age. Infection starts as early as mid-adolescence in resource-limited countries; later in high-income countries. The majority of childhood infections are asymptomatic or mild. Infections in adolescence or young adults are much more likely to cause symptomatic infection known as infectious mononucleosis ("mono"). Following the initial infection the virus stays in a long term latency, usually incorporated in B cells.

A concise, clinically useful lifecycle to keep in mind:
1. Infection & entrance: The most common medium through which EBV may be transmitted is saliva (kissing, sharing utensils etc). The virus enters the mouth and throat (oropharyngeal) epithelial cells. It then enters the B lymphocytes.

2. Primary (lytic) infection: Virus replication is typically 48 to 60 days after exposure. In some with no symptoms, the classical mononucleosis syndrome (fever, pharyngitis, lymphadenopathy, profound fatigue) develops.

3. Latency: The virus is in the form of latent program in B lymphocytes (scarce or no viral genes translation). In the latency phase, the virus remains dormant throughout life, and generally it is covered by immune surveillance.

4. Reactivation (periodic lytic replication): EBV can periodically reactivate (usually without causing symptomatic disease). Reactivation can be accompanied by clinical issues in the immunocompromised (i.e., transplant recipients, those with advanced HIV), more frequently than in others

Infectious mononucleosis is a clinical condition with a maiden viral infection involving Epstein-Barr virus (EBV). It is traditionally described as a triad of deep fatigue, sore throats and lymph node swelling, although fever and headache as well as fluctuating elevations in liver enzymes may be present. Mono is a syndrome and not a single-pathogen term: EBV causes the majority of them, but there are other virus infections i.e. CMV, adenovirus, acute HIV, toxoplasmosis.

Compared to most respiratory viruses, it has a prolonged incubation period following exposure; typically, symptoms of infection manifest themselves after 4-6 weeks, in very young children, it may be a little earlier. The infection typically starts with non-specific symptoms of low-grade fever, intermittent malaise and myalgias during the first few days followed by an acute phase characterized by high fever, severe sore throat and tender cervical lymphadenopathy and marked fatigue. With most symptomatic patients, the improvement will be seen in 2-4 weeks yet fatigue and lymph node enlargement might take weeks and even months to disappear in some patients. Patients with proceeding and no obvious causes of the symptom that sets in after the 6 th month should be assessed with other causes of chronic fatigue.

Most EBV infections that occur during childhood do not produce any recognizable illness or only a mild nonspecific febrile illness. After adolescence or young adulthood, an individual is far more likely to develop symptomatic mono with its primary EBV infection. After the primary EBV infection, whether symptomatic or not, the virus establishes lifelong latency within B cells. Most people will therefore carry antibodies to EBV; however, very few will actually go on to develop the complete syndrome of mono.

The EBV is practically found in all parts of the globe. The majority of children in the low-resource settings are mainly infected at an early age and they remain asymptomatic. In high-income settings, there is typically a delay in the first exposure until adolescence, therefore increasing the likelihood of symptomatic mono. Most people have evidence of prior EBV infection by serology, with an approximate 90-95 percent seroprevalence.

The most common modes of transmission are saliva, or kissing, sharing a drink or cutlery or even through contact with an object that touched the saliva. It is also spread via genital secretions, blood and organ transfer in some cases. Notably, following primary infection, the individual may shed EBV a few weeks and potentially even longer during reactivation. Hence infectiousness may potentially start before symptoms develop, and continue subsequently as well.

Immunocompromised patients, those with advanced HIV, and those on immunosuppression, are susceptible to some severe primary infections, they are prone to some reactivation of symptoms and to EBV lymphoproliferative disorders and this is why they are often observed using quantitative PCR.

Occupational or household exposure raises the risk of repetitive exposures without necessarily producing symptoms, in case the person is already infected (workers in the medical field, those who take care of young children).

Infectious mononucleosis typically presents with a triad of severe fatigue, sore throat, and tender cervical lymph node enlargement, usually with fever, headache, and generalized myalgias. As compared to laboratory results where abnormal (reactive) lymphocytes and elevated liver enzymes would be detected as the probable outcome.

Symptoms typically appear 4-6 weeks following exposure, reach their peak in the following 1-3 weeks and most individuals have their first signs of improvement within 2-4 weeks with residual fatigue persisting in many individuals 2-6 weeks after the occurrence of the initial symptoms.

Although the majority of cases are limited in nature EBV mono can lead to:

1. Severe tonsillitis with airway obstruction
2. Significant hepatic dysfunction (hepatitis)
2. Hematological issues (severe neutropenia, autoimmune hemolytic anemia, thrombocytopenia)
4. Neurological complications (encephalitis, meningitis, Guillain—Barré syndrome)
5. Splenic enlargement, which rarely leads to a splenic rupture.

These are rare but clinically important complications because they change management and disposition management.

In case you find any evidence of severe airway obstruction or tonsillar swelling, signs of splenic rupture (i.e., acute and sudden left upper quadrant pain that radiates to the shoulder, which also includes a possible incidence of hypotension in the patient), severe jaundice, or liver failure, severe cytopenia (i.e., Tremendous deficiency of platelets or white blood cells), neurological defects, or hemodynamic instability, then please refer the patient to the ED or take him/her to the hospital.

Complete Blood Count (CBC) with differential (for lymphocytosis/atypical lymphs), LFTs (ALT/AST, bilirubin), platelet count, and a heterophile antibody (Monospot) test if the patient is older than early childhood and you want a rapid screen. These tests are useful for determining severity and need for follow-up.

The Monospot test detects heterophile antibodies and can be a fast positive screen for typical adolescent/young adult mono but does have false negatives (especially in children and early in the disease) and false positives due to other conditions. Therefore, it should not be used as the only confirmatory test when there is diagnostic uncertainty; serologic panels are preferred for exact disease staging.

EBV-specific serology (interpretation primer). A standard panel will usually contain the following:

1. VCA-IgM: Apparent early in primary infection, usually disappearing in ~4-6 weeks.
2. VCA-IgG: Appears in acute infection, peaks in weeks, and persists for life.
3. IgG for EA (early antigen): Can be present in acute infection and sometimes in reactivation; a minority (around 20%) of healthy individuals may harbor persistent EA antibodies.
4. EBNA IgG: Mostly absent in acute primary infection, appears within 2-4 months after onset of infection. Its presence usually indicates past infection.

Imaging is not usually performed in simple cases of mononucleosis. Reserve ultrasound or CT for specific concerns. A focused abdominal ultrasound will be the first-line test when there is significant left upper-quadrant pain. Also, perform ultrasound or CT when suspicion is raised about splenic enlargement or rupture, with considerations for hemodynamic instability (pain, hypotension, anemia).

CT is preferred in the setting of unstable patients or if findings on ultrasound are equivocal but clinical suspicion for rupture or intra-abdominal bleeding is high. Several case series and reviews highlight that splenic rupture, although rare, is life-threatening when it occurs and typically presents with acute LUQ pain or referred shoulder pain (Kehr sign) and either hypotension or falling hemoglobin.

Check the oropharynx carefully in patients with severe tonsillar hypertrophy, muffled voice, stridor, drooling, or progressive respiratory distress. When there is threatened airway compromise (severe tonsillar swelling, stridor, hypoxia), consider urgent ENT consultation for bedside airway assessment and possible admission for monitoring and corticosteroids or airway intervention. Steroids can counteract tonsillar/airway edema in selected, severely obstructed patients (see treatment below).

There is no antiviral therapy proven to shorten uncomplicated EBV mono in everyday practice. The management is thus concentrated on rest, hydration, analgesia/antipyretics (acetaminophen or NSAIDs as clinically appropriate), and monitoring of complications. Patients are to be counseled that often fatigue can last longer than other symptoms and graded return to activity is the safest approach.

A characteristic maculopapular rash commonly occurs in EBV patients who receive ampicillin or amoxicillin, while the mechanism is likely immune-mediated, and in most cases is not a true penicillin hypersensitivity. Nevertheless, the reaction is so commonly encountered that physicians ought not to give these antibiotics empirically in cases of pharyngitis unless streptococcal infection is confirmed. When streptococcal infection is suspected, a rapid strep test should be performed or a throat culture taken to confirm diagnosis before beta-lactam treatment.

These include splenomegaly and very rare spontaneous rupture, confined spaces from tonsillar swelling, acute inflammation of the liver, hematological disorders such as a very severe degree of cytopenias and autoimmune hemolysis, and neurological complications such as encephalitis or Guillain-Barré. For early recognition and involvement of specialty services to preclude morbidity.

Many cancers are defined in cases where, in fact, EBV has a specific linkage to its cause, like endemic Burkitt lymphoma; certain subtypes of Hodgkin lymphoma; nasopharyngeal carcinoma especially in some geographic and ethnic groups; and a smaller fraction of gastric carcinomas.

Epstein Barr Virus Lymphomas and Epithelial Cancers in Humans (Journal of Cancer)

The cancer hazard in EBV-infected persons is very low, considering that any person almost certainly will be infected with EBV at some point in their life and cancer development usually depends on latency patterns of the virus, genetics of the host, cofactors like malaria in the endemic cases of Burkitt lymphoma, and environmental exposures. Current reviews express the pathobiology and upcoming therapies directed at EBV.

Studies found strong temporal evidence of EBV infection as a precursor of MS. Again, this raises the profile of EBV as one of the most important environmental risk factors in the pathogenesis of MS. Some important clarifications include the point that EBV may be an incredibly significant environmental trigger in many cases, but it is not sufficient alone to cause MS genetic susceptibility and other factors must be present. These findings have increased momentum for EBV vaccine research as a potential strategy for MS prevention.

1. How long have I been contagious?
EBV shedding can happen for weeks during primary sickness and intermittently thereafter, spreading to potential others. There is no such thing as a "safe day" test. During subsequent weeks, however, limit close saliva exchange whenever illness is present.

2. Can I kiss my partner?
Not while the symptoms are present and for several weeks after, as kissing implies an exchange of bodily fluids, and could potentially end up spreading the virus. If the partner is already EBV-seropositive (as is normally the case in adults), he or she will usually not become ill anew.

3. Can I get mono more than once?
True instances of repeated primary mono are infrequent because the bulk of the infected develop long-lasting immunity. The exception would be when EBV lays dormant as a much less active virus (often without significant symptoms in humans) and is provoked back to action either by itself or by another mono-like virus.

The Epstein-Barr virus (EBV) is almost widespread and harmless except in cases of primary infection during adolescence or adulthood, in which case it may cause infectious mononucleosis,a recognizable clinical syndrome that is often self-limited. Sometimes, it is complicated by splenomegaly, airway compromise, significant liver involvement, or hematologic or neurologic problems.

Correct diagnosis will rely on a timely and suitable selection of tests: rapid screening of heterophile tests on the very elderly; EbV-specific serology for other age groups (with PCR in the immunocompromised patient) for staging. Keep in mind that serology cannot replace a thorough patient history and careful examination.

1. About Epstein-Barr virus (EBV). (2024, May 9). Epstein-Barr Virus and Infectious Mononucleosis. 

2. Cesarman, E. (2011). Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Letters, 305(2), 163–174.

3. Fletcher, J. (2023, March 29). What to know about hemodynamic instability.

4. Hoover, K., & Higginbotham, K. (2023, August 8). Epstein-Barr virus. StatPearls - NCBI Bookshelf. 

5. Leonard, J. (2024, October 1). What does a maculopapular rash look like? 

6. Mononucleosis (Mono) tests. (n.d.). 

7. Multiple sclerosis - Symptoms and causes. (n.d.). Mayo Clinic. 

8. O’Connell, K. (2019, July 4). What causes malaise? Healthline. https://www.healthline.com/health/malaise

9. Professional, C. C. M. (2025a, June 30). NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). Cleveland Clinic. 

10. Professional, C. C. M. (2025c, July 15). Myalgia (Muscle pain). Cleveland Clinic. 

11. Schönrich, G., Abdelaziz, M. O., & Raftery, M. J. (2022). Epstein-Barr virus, interleukin-10 and multiple sclerosis: A ménage à trois. Frontiers in Immunology, 13. 

12. Tonsillitis. (2025, August 15). Cleveland Clinic. 

13. Wikipedia contributors. (2025a, June 22). B cell. Wikipedia. 

14. Wikipedia contributors. (2025b, July 17). Herpesviridae. Wikipedia.